Year-End Report 2005

Fourth Quarter and Full Year Results 2005

- Net sales amounted to 138.4 MSEK (106.2) in the fourth quarter and to 430.4 MSEK (366.6) for the full year 2005. - Operating profit amounted to –4.7 MSEK (0.6) in the fourth quarter and to –62.9 MSEK (–61.7) for the full year 2005. - The net result for the fourth quarter amounted to 0.4 MSEK (–10.8) and to –39.9 MSEK (–74.7) for the full year 2005. - Earnings per share in the fourth quarter amounted to 0.01 SEK (–0.19) and to –0.57 SEK (–1.29) for the full year 2005. - The cash flow from the current business was positive in the fourth quarter. - In June the business of the American company Argonaut was acquired and the integration has proceeded according to plan during the year. - In October Separtis Holding AG, distributor of many of Biotage’s products in Switzerland, Germany and Austria, was acquired. - The new share issue completed in November was fully subscribed and provided the company approx. 48.3 MSEK before deduction of issue expenses. - In January 2006 exclusive distribution, production and further development rights to Vapourtec’s solvent evaporation system V-10 were acquired. Contact: Jeff Bork, President and CEO Tel: +46 734-22 16 60 Mats-Olof Wallin, CFO Tel: +46 705-93 52 73

About Us

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry, medicinal chemistry, separation and purification. The customers include pharmaceutical and biotech companies, companies within the food industry and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has approx. 290 employees and had sales of 463 MSEK in 2012. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: